Enolase Inhibitor

AP-III-a4 (ENOblock) is a nonsubstrate analogue enolase inhibitor with an IC₅₀ of 0.576 uM. AP-III-a4 can be used for the research of cancer and diabetic.

D-(-)-3-Phosphoglyceric acid (3-Phospho-D-glyceric acid) disodium is an important intermediate in the enzyme-catalyzed glycolysis process. D-(-)-3-Phosphoglyceric acid disodium competitively inhibits yeast enolase (enolase). D-(-)-3-Phosphoglyceric acid disodium can regulate the activity of phosphoglycerate dehydrogenase (PHGDH) to modulate p53 protein and apoptosis.

POMHEX, a racemic mixture and a cell-permeable pivaloyloxymethyl (POM) proagent of HEX, is a potent, ENO2-specific inhibitor of enolase. POMHEX exhibits low-nanomolar potency against ENO1-deleted cells in vitro and is capable of eradicating ENO1-deleted xenografted tumours in vivo. POMHEX is a potent glycolysis inhibitor.

SF2312, a natural phosphonate antibiotic (Antibiotic), is a highly potent Enolase inhibitor with IC₅₀s of 37.9 nM and 42.5 nM for human recombinant ENO1 and ENO2, respectively. SF2312 is active against bacteria under anaerobic conditions.

AP-III-a4 (ENOblock) hydrochloride is a nonsubstrate analogue enolase inhibitor with an IC₅₀ of 0.576 uM. AP-III-a4 hydrochloride can be used for the research of cancer and diabetic.

Anti-ENO1 Antibody is an anti-ENO1 antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

Anti-EPO Antibody is an anti-EPO antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

Hex is an enolase inhibitor and antimalarial agent with K_i values of 74.4 nM and 269.4 nM for ENO2 and ENO1, respectively. Hex is a NfENO and TbENO inhibitor with IC₅₀s value of 0.14 μM and 2.1 μM, respectively. Hex has antimalarial activity against Plasmodium falciparum 3D7, Naegleria fowleri trophozoites and Plasmodium berghei ANKA strain. Hex has anti-tumor effects against intracranial tumors.

SU212 is a podophyllotoxin-derived ENO1 inhibitor and AMPK activator. SU212 can selectively induce oxidative phosphorylation, reduce glycolysis activity and glucose uptake in tumor cells, and directly bind to ENO1 without affecting these pathways in normal cells. SU212 induces apoptosis and promotes ENO1 degradation via proteasomal and autophagic pathways without inhibiting the catalytic activity. SU212 leads to mitotic arrest and apoptosis in TNBC (triple-negative breast cancer) cells by activating AMPK, demonstrating potent anti-tumor activity in vitro. SU212 inhibits tumor growth and metastasis in syngeneic, xenograft, and diabetic mouse models, exhibiting an excellent safety profile. SU212 can be used in research on t TNBC, diabetes, and fatty liver disease.

PSP-0119 is a highly efficient and effective PROTAC degrader targeting IRAK4 (IC₅₀ = 2.83 nM). PSP-0119 can inhibit IRAK4 kinase activity, NF-κβ activity, and IL-1β-induced IRAK4 phosphorylation. PSP-0119 degrades IRAK4 in FLT3-mutant AML cell lines, sparing FLT3-wild-type AML cells, FLT3-wild-type samples, and normal bone marrow. PSP-0119 downregulates alpha-enolase (eNOS) of MOLM-13 cells. PSP-0119 can be used for the study of Acute Myeloid Leukemia (AML).

SF2312 ammonium is a phosphonate Antibiotic and Enolase inhibitor, with an IC₅₀ of 18.4 nM against E. coli enolase. SF2312 ammonium reduces intracellular ATP levels and inhibits glycolytic flux. SF2312 ammonium exhibits activity against both Gram-positive and Gram-negative bacteria, and exerts synergistic effects against E. coli when combined with Fosfomycin (HY-B1075A). SF2312 ammonium shows selective toxicity toward gliomas with ENO1 gene knockout. SF2312 ammonium can be used in research related to bacterial infections and gliomas.

HuL001 is a specific monoclonal antibody targeting ENO1. HuL001 remodels the tumor microenvironment by inhibiting cancer-associated fibroblasts, thereby suppressing the progression of multiple myeloma. HuL001 can be used for research on cancers such as colorectal cancer, pancreatic ductal adenocarcinoma, and myeloma.